Endo Investors

Cecelia Health, Inc. is a technology-enabled company that specializes in remote telehealth support and chronic disease management in the United States. Founded in 2009 and headquartered in New York, it focuses on providing clinical support and coaching to individuals with Type 1 and Type 2 diabetes, as well as those dealing with obesity and cardiovascular diseases. Cecelia Health combines expert clinical coaching with digital health solutions, enabling patients to adhere to medication and wellness programs. The company offers virtual care as an alternative to traditional in-person visits, particularly enhancing access during the COVID-19 pandemic. Through a personalized coaching approach, Cecelia Health aims to improve patient self-management and health outcomes, serving both patients and healthcare partners effectively.

Capillary Biomedical, Inc. is a medical device company founded in 2014 and located in Irvine, California. The company focuses on developing innovative technologies for diabetes management, particularly in simplifying glucose monitoring and insulin delivery. As a spin-out from the Artificial Pancreas Center at the Sidney Kimmel Medical College of Thomas Jefferson University, Capillary Biomedical is dedicated to reducing the burden of diabetes on patients and the healthcare system. Its flagship product features a kink-proof, flexible, multiport cannula designed for reliable and comfortable insulin delivery, with an emphasis on a straightforward one-handed insertion process. This user-friendly design aims to assist diabetes patients in achieving better blood glucose control.

Bigfoot Biomedical, Inc. is a healthcare company focused on improving diabetes management for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company develops an advanced diabetes management system that integrates automated insulin delivery with cloud connectivity and user-friendly automation. This system aims to optimize insulin dosing and delivery through a cohesive ecosystem of medical devices, including an automated infusion pump and a connected insulin pen. Leveraging machine learning and secure consumer technologies, Bigfoot Biomedical provides a comprehensive digital platform that addresses the cognitive, emotional, and financial challenges associated with diabetes management. The company's innovative approach includes a first-of-its-kind monthly subscription service model, making diabetes care more accessible and efficient for patients.

Mellitus Health, Inc. is a healthcare technology company based in Los Angeles, California, that specializes in cloud-based insulin titration software. The company has developed Insulin Insights, an application designed to provide clinicians with precision insulin dosage recommendations. This tool allows for patient-specific dosage adjustments, enabling healthcare providers to optimize insulin regimens effectively. By facilitating more accurate insulin management, Mellitus Health aims to reduce blood glucose levels, minimize complications, and ultimately lower healthcare costs associated with diabetes treatment. Founded in 2013, the company focuses on improving the quality of care for patients requiring insulin therapy.

Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.

ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial. ILiAD Biotechnologies is a registered Delaware company founded in 2012.